Kengo Nagashima

79PUBLICATIONS
243CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedSport and exercise nutritionPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (79)

|Sep 05, 2026
PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

|Sep 02, 2026
Study of weight loss intervention to find an effective strategy for obesity management and the TARGET of weight loss amount for reducing health disorders (SLIM-TARGET): a randomized controlled trial.

|Aug 08, 2026
Monitoring with plasma apolipoprotein A2-isoforms can predict developing new-onset steatotic liver disease caused by pancreatic exocrine insufficiency following pancreatectomy.

|Jul 06, 2026
Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.

|Mar 28, 2026
A Pancreatic Ductal Adenocarcinoma Diagnostic System Using Serum Extracellular Vesicle Detection with Optimized Lectin Combination Using Machine Learning.

Tatsuya Kawakami, Sho Uemura, Masayuki Ono

|Feb 17, 2026
Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma.

Jun Okui, Satoru Matsuda, Kengo Nagashima

Pageof 14

Frequent Collaborators

10 joint publications

Misuzu Fujita

6 joint publications

Jun Okui

6 joint publications

Satoru Matsuda

5 joint publications

Hisashi Noma